You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

Details for Patent: 7,488,827

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,488,827 protect, and when does it expire?

Patent 7,488,827 protects ANORO ELLIPTA, INCRUSE ELLIPTA, and TRELEGY ELLIPTA, and is included in three NDAs.

This patent has sixty-one patent family members in thirty-six countries.

Summary for Patent: 7,488,827

Title:	Muscarinic acetylcholine receptor antagonists
Abstract:	Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Inventor(s):	Laine; Damane I. (King of Prussia, PA), Palovich; Michael R. (King of Prussia, PA), McCleland; Brent W. (King of Prussia, PA), Neipp; Christopher E. (King of Prussia, PA), Thomas; Sonia M. (King of Prussia, PA)
Assignee:	Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:	11/774,867
Patent Claim Types: see list of patent claims	Compound; Composition; Delivery;

Drugs Protected by US Patent 7,488,827

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Glaxo Grp England	INCRUSE ELLIPTA	umeclidinium bromide	POWDER;INHALATION	205382-001	Apr 30, 2014		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,488,827

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1740177	⤷ Sign Up	C300694	Netherlands	⤷ Sign Up
European Patent Office	1740177	⤷ Sign Up	CA 2014 00052	Denmark	⤷ Sign Up
European Patent Office	1740177	⤷ Sign Up	PA2014038	Lithuania	⤷ Sign Up
European Patent Office	1740177	⤷ Sign Up	92565	Luxembourg	⤷ Sign Up
European Patent Office	1740177	⤷ Sign Up	1490060-9	Sweden	⤷ Sign Up
European Patent Office	1740177	⤷ Sign Up	14C0075	France	⤷ Sign Up
European Patent Office	1740177	⤷ Sign Up	C20140032 00132	Estonia	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.